10. Immune reconstitution  by Chao, N.J.
10
IMMUNE RECONSTITUTION
Chao, N.J. Department of Medicine and Immunology, Division of Cel-
lular Therapy/BMT, Duke University, Durham, NC
An important milestone following allogeneic stem cell transplan-
tation is the full recovery of immune function. Recovery of immu-
nity involves reconstitution of the innate as well as the adaptive
immune cells and their respective function. The most extensively
studied component is the lymphocyte compartment. T-cell recon-
stitution early on following cord blood transplantation involves
expansion of the initial cord blood T cells infused with the stem
cells. This ﬁrst wave of T cells are a result of peripheral expansion
in secondary lymphoid organs. Following peripheral expansion,
there is a slower second wave of donor-derived precursors that
come from the engrafted donor cells. These cells trafﬁc through
the thymus and are educated there. T-cell receptor excision circles
(sjTRECs) are generated within the thymus and identify new
thymic emigrants and those that have not divided. Measurements
of TRECs, spectratyping of the T cell receptor Vbeta families and
extensive phenotypic analyses have allowed us to determine the
time course of T cell reconstitution and some of the factors which
contribute or detract from rapid recovery. sjTRECs were detected
at normal levels in all children starting 12 months after transplant.
sjTRECs were not detected until 18 months after transplant in
adults and then only at a three-fold lower level than expected for
age. T-cell repertoires were skewed in adults and children between
12 and 18 months after transplant, but recovered to near-normal
diversity at between 2 and 3 years. T-cell repertoires appeared
more diverse earlier in children (at 1-2 years) than in adults (at 3-4
years). Thus, T-cell recovery after UCB transplant occurs primar-
ily through peripheral expansion of adoptively transferred donor
T-cells and results in skewing of the T-cell repertoire. The re-
appearance of sjTREC containing cells after UCB transplant is
associated with increasing numbers of phenotypically naïve T-cells,
improved mitogen and recall antigen responses and diversiﬁcation
of the T-cell repertoire. The delay in central T-cell recovery in
adults relative to children may be due to differences in thymic
function resulting from age-related atrophy, graft-versus-host dis-
ease (GVHD) or the pharmacologic effects of prophylaxis and
treatment of GVHD.
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REGULATORY T-CELLS AND CORD BLOOD
Blazar, B.R. University of Minnesota Cancer Center and Department of
Pediatrics, Division of BMT
A subpopulation of naïve CD4 T cells that co-expresses CD25,
the IL-2R alpha chain, has been shown to have potent suppressor
activity. The frequencies of CD4CD25bright cells are higher in
rodents than in humans (8-12% vs 1-3%, respectively, of CD4 T
cells). CD4CD25 cells have been shown to play a vital role in
the induction and maintenance of peripheral self-tolerance and
prevention of systemic autoimmune disorders, including autoim-
mune gastritis, intestinal inﬂammation, and autoimmune diabetes
in diabetes-prone (non-obese diabetes: NOD) mice. Sakaguchi
found that nude mice rejected allogeneic skin grafts faster if trans-
ferred lymphocytes were ﬁrst depleted of CD25 cells indicating
that CD25 cells suppress alloresponses. We have shown that
CD4CD25 regulate T cell alloresponses and tolerance induc-
tion. Depletion of CD425 cells augments a mixed lymphocyte
reaction (MLR) culture whereas adding a graded number of
CD4CD25 T cells resulted in a dose-response reduction in
alloproliferation. Costimulatory pathway blockade can induce tol-
erance to alloantigens in MLR cultures; depletion of CD425
cells from the responder population precludes tolerance induction,
while addback of cells restores tolerance induction revealing an
important role for CD425 cells in this form of tolerance in-
duction. Several laboratories including ours have shown that
CD425T cells present in the donor spleen graft downregulates
graft-versus-host disease (GVHD) lethality while CD4CD25
cells depletion from the donor graft prior to in vivo infusion
resulted in accelerated GVHD morbidity and increased mortality
indicating that CD4CD25 cells play a role in regulation of
GVHD. Supplementation of the donor graft with donor but not
host CD425 cells had a marked amelioration of GVHD lethal-
ity in multiple strain combinations. CD4CD25 cells became
more potent suppressor cells after activation and expansion with
anti-CD3 mAb and IL-2. Therefore, it is not surprising that ex
vivo activation and expansion of CD425 cells by exposure to
reagents that induce TCR ligation and in the presence of a high
concentration of IL-2 resulted in signiﬁcant expansion of this cell
population and increased their anti-GVHD potency. Expansion of
CD425 cells could be achieved by exposure to anti-CD3 mAb
or alloantigen-bearing antigen-presenting cells in the presence of
IL-2. Elucidation of other mechanisms by which activated CD25
cells inhibit GVHD remains unclear. The literature suggests sev-
eral possibilities that are not necessarily mutually exclusive. In vitro
suppression is dependent upon cell-cell contact. Data from Naka-
mura et al suggested that cell surface-bound TGF	 was responsible
for the cell contact-dependent suppression, in contrast to data from
Shevach and colleagues. Thornton and Shevach showed that
CD4CD25 T cells block IL-2 production by the
CD4CD25
 cells at the RNA transcription level. The relative
IL-2 paucity could inhibit the activation, proliferation and effector
function of both CD4CD25
 and CD8 T cells. Other data
indicate that CD152, glucocorticoid-induced TNF receptor
(GITR), or the transcription factor, FoxP3, in CD4CD25 cells
or the activation of CD4CD25 cells by signaling of toll-like
receptors each play an important role in their regulatory function.
Of clinical signiﬁcance, three groups have shown that CD425
cells do not inhibit a GVL effect. Edinger et. al. demonstrated that
cytolytic T cell mediated killing of two different B cell leukemia/
lymphoma cell lines was preserved despite inhibition of GVHD
lethality by CD425 cell infusion. Jones et al showed that
CD8 T cell mediated GVHD was inhibited without precluding
elimination of acute myeloid leukemia cells if CD425 cells
were administered 10 days post-BMT. Trenado et al demonstrated
that ex vivo expanded CD425 cells controlled GVHD but did
not inhibit elimination of a B cell leukemia/lymphoma cell line in
contrast to the graft-versus-tumor (GVT) response to a mastocy-
toma cell line which was impaired. Collectively, these preclinical
data indicate that Tregs inhibit GVHD with the retention of
GVL/GVT in many instances. CD425 T cells are heteroge-
neous in their expression of cell surface antigens. For example,
about 2/3 of CD425 T cells express high levels of the lymph
node (LN) homing receptor, L-selectin (CD62L). Although both
L-Selhi and L-Sello CD425 subsets have in vitro suppressor
function, LSelhi Tregs could have superior therapeutic beneﬁt due
to inhibition of critical early GVHD priming events because of
their ability to home to peripheral LNs via the binding of the L-Sel
molecule to determinants on high endothelial venules in these
LNs. Initial homing of L-Selhi Tregs to the LNs would optimize
the likelihood of interfering with the priming and expansion of
effector T cells thereby inhibiting an early phase of GVHD. Using
whole body imaging, we have demonstrated that LSelhi CD425
cells reduced numbers of green ﬂuorescent protein (GFP) effec-
tor T cells in many types of tissues besides lymphoid organs.
Despite the presumed ability of LSello CD425 cells to migrate
directly to sites of inﬂammation, imaging data indicate little de-
monstrable effect on the accumulation of GFP T cells in GVHD
target organs in LSello-treated mice. In other studies, Ermann et al
conﬁrmed these ﬁndings and reported that only the L-Selhi subset
of CD425 T cells prevented severe tissue damage to the colon
and protected recipients from lethal acute GVHD and concluded
that the ability of Treg cells to efﬁciently enter the priming sites of
pathogenic allo-reactive T cells appears to be a prerequisite for
their protective function in acute GVHD. Thus, optimization of
the homing and migration patterns of CD425 cells may be
critical in achieving the most potent anti-GVHD effects. Since
CD4CD25 cells are capable of suppressing both CD4 and
CD8T cells, it is reasonable to presume that CD4CD25 cells
may be beneﬁcial in suppressing host anti-donor responses that can
cause BM graft rejection. This has now been demonstrated by 3
separate groups using distinct model systems. Joffre et al showed
that preactivated CD425 cells prevented allogeneic BM graft
rejection by host splenocytes given to lethally irradiated recipients.
We have shown that L-selhi but not L-sello preactivated and ex-
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